文献速递小儿神经外科与脑积水

可调压(proSA®)与固定压(SHUNTASSISTANT®)重力阀在儿童脑积水患者中的比较:一项16年回顾性单中心对比研究及生物力学分析

Programmable (proSA®) vs. fixed (SHUNTASSISTANT®) gravitational valves in pediatric patients with hydrocephalus: a 16-year retrospective single-center comparative study with biomechanical analysis.
PubMed 文献 · Acta Neurochir (Wien) · 2023-08-29

该回顾性单中心研究分析了2006年1月至2022年1月间244例非肿瘤病因儿童脑积水患者植入的391个重力阀(254个SA®,137个proSA®),比较可调压与固定压重力阀的存活率及相关因素。结果显示两组阀存活率无显著差异(P=0.245),植入时年龄<2岁与显著较低的阀存活率相关(P<0.001),proSA®组因调压系统功能障碍导致的更换比例较高(45.3%)。作者认为可调压可能有助于预防慢性过度引流的后遗症,但不减少翻修需求,可考虑在特定>2岁生长中儿童中使用proSA®阀。

要点

  • proSA®与SA®重力阀在儿童脑积水中的存活率无显著差异(P=0.245)。
  • 植入时年龄<2岁与显著较低的阀存活率相关(P<0.001)。
  • proSA®组阀更换的首要原因为调压系统功能障碍(45.3%)。

核心结论

  • proSA®与SA®重力阀在儿童脑积水中显示出相似的存活率,与病因无关,仅与植入时低年龄相关。
  • 可调压可能有助于预防慢性过度引流的后遗症,但不减少阀翻修需求,作者认为在特定>2岁生长中儿童中可考虑使用proSA®阀。

研究设计与样本

  • 回顾性单中心研究,分析2006年1月至2022年1月间接受固定压(SA®)或可调压(proSA®)重力阀治疗的non-tumoral病因儿童脑积水患者的临床记录和影像。
  • 共纳入244例患者(134例男性),植入391个重力阀(254个SA®,137个proSA®)。
  • 比较阀存活率与年龄和病因的关系,并对近期取出的阀进行生物力学分析。

主要发现

  • 随访81.1±46.3个月期间,133个SA®(52.4%)和67个proSA®(48.9%)被取出。
  • proSA®组1年和5年阀存活率分别为87.6%和60.6%,SA®组分别为81.9%和58.7%,平均存活时间分别为56.4±35.01个月和51.4±43.0个月(P=0.245)。
  • 植入时年龄<2岁与显著较低的阀存活率相关(P<0.001),脑积水病因无显著影响。
  • 单纯过度引流导致的翻修在SA®组更多(39.8% vs 3.1%,P<0.001),而调压系统功能障碍是proSA®组阀更换的首要原因(45.3%)。
  • 对41个proSA®和31个SA®阀的生物力学分析显示,阀内表面沉积物分别见于97.6%和90.3%的病例。

临床怎么用

  • 作者认为可调压可能有助于预防慢性过度引流的后遗症,但不减少阀翻修需求。
  • 作者建议在特定>2岁生长中儿童中可考虑使用proSA®阀。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In pediatric hydrocephalus (HC) treatment, programmable gravitational valves offer greater flexibility to manage overdrainage during children's growth. However, it remains unclear whether these devices provide better outcomes rather than their precursors. The study assessed the benefit from programmability of gravitational valve, i.e., programmable-SHUNTASSISTANT (proSA®) vs. SHUNTASSISTANT® (SA®). METHODS: Clinical records and imaging of pediatric patients with hydrocephalus of non-tumoral etiology treated with fixed (SA®) or programmable (proSA®) gravitational valves between January 2006 and January 2022 were analyzed in a retrospective single-center study. Valve survival was compared in relation to age and etiology. Lately explanted valves received biomechanical analysis. RESULTS: A total of 391 gravitational valves (254 SA® and 137 proSA®) were inserted in 244 patients (n = 134 males). One hundred thirty-three SA® (52.4%) and 67 proSA® (48.9%) were explanted during a follow-up of 81.1 ± 46.3 months. Valve survival rate at 1 and 5 years with proSA® was 87.6% and 60.6% compared to 81.9% and 58.7% with SA®, with mean survival time 56.4 ± 35.01 and 51.4 ± 43.0 months, respectively (P = 0.245). Age < 2 years at implantation correlated with significantly lower valve survival rates (P < 0.001), while HC etiology showed no significant impact. Overdrainage alone accounted for more SA® revisions (39.8% vs. 3.1%, P < 0.001), while dysfunctions of the adjustment system represented the first cause of valve replacement in proSA® cohort (45.3%). The biomechanical analysis performed on 41 proSA® and 31 SA® showed deposits on the valve's internal surface in 97.6% and 90.3% of cases. CONCLUSION: Our comparative study between proSA® and SA® valves in pediatric HC demonstrated that both valves showed similar survival rates, regardless of etiology but only with young age at implantation. The programmability may be beneficial in preventing sequelae of chronic overdrainage but does not reduce need for valve revision and proSA® valve should be considered in selected cases in growing children older than 2 years.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Issa M, Paggetti F, von Hardenberg A, et al. Programmable (proSA®) vs. fixed (SHUNTASSISTANT®) gravitational valves in pediatric patients with hydrocephalus: a 16-year retrospective single-center comparative study with biomechanical analysis. Acta Neurochir (Wien). 2023. PMID: 37640980. doi:10.1007/s00701-023-05751-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。